Background: Acute exacerbation of interstitial lung disease (AE-ILD) is a severe complication with a poor prognosis. No clinical trials have supported the use of rituximab in AE-ILD associated with connective tissue disease.
Methods: We present a series of four cases in which administration of rituximab was associated with appropriate clinical, radiological and functional progress.
Results: The four patients were alive 30 days after discharge following their exacerbation.
Conclusions: Given the speed of action, safety and efficacy profile observed for rituximab, we believe that this agent should be further investigated in clinical trials so that it could be included in the daily clinical management of this severe condition.
Keywords: Autoimmune Diseases; Pulmonary Fibrosis; Rituximab; Treatment.
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.